These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1395 related articles for article (PubMed ID: 32273594)
1. COVID-19: immunopathology and its implications for therapy. Cao X Nat Rev Immunol; 2020 May; 20(5):269-270. PubMed ID: 32273594 [TBL] [Abstract][Full Text] [Related]
3. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Cox RJ; Brokstad KA Nat Rev Immunol; 2020 Oct; 20(10):581-582. PubMed ID: 32839569 [TBL] [Abstract][Full Text] [Related]
4. Recommendations for caring for patients with severe and nonsevere COVID-19. Paladugu S; Donato AA Ann Intern Med; 2020 Jul; 173(2):JC3. PubMed ID: 32687760 [TBL] [Abstract][Full Text] [Related]
5. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19. Morabito CJ; Gangadharan B Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691 [No Abstract] [Full Text] [Related]
6. Potential strategies for combating COVID-19. Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950 [TBL] [Abstract][Full Text] [Related]
7. The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy. Borlongan MC; Borlongan MC; Sanberg PR Cell Transplant; 2020; 29():963689720940719. PubMed ID: 32841042 [TBL] [Abstract][Full Text] [Related]
8. Convalescent serum lines up as first-choice treatment for coronavirus. Sheridan C Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594 [No Abstract] [Full Text] [Related]
9. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. Goodarzi P; Mahdavi F; Mirzaei R; Hasanvand H; Sholeh M; Zamani F; Sohrabi M; Tabibzadeh A; Jeda AS; Niya MHK; Keyvani H; Karampoor S Int Immunopharmacol; 2020 Nov; 88():106885. PubMed ID: 32795893 [TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Xi Y Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211 [No Abstract] [Full Text] [Related]
11. Convalescent Plasma: Promise for COVID-19 Pandemic. Sheikh S; Baig MA J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468 [No Abstract] [Full Text] [Related]
12. The convalescent sera option for containing COVID-19. Casadevall A; Pirofski LA J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489 [No Abstract] [Full Text] [Related]
13. Evidence lags behind excitement over blood plasma as a coronavirus treatment. Ledford H Nature; 2020 Aug; 584(7822):505. PubMed ID: 32820261 [No Abstract] [Full Text] [Related]
14. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. Kouzy R; Abi Jaoude J; Garcia Garcia CJ; El Alam MB; Taniguchi CM; Ludmir EB JAMA Netw Open; 2020 Jul; 3(7):e2015100. PubMed ID: 32658285 [TBL] [Abstract][Full Text] [Related]
15. Plasma Therapies and Parabiosis in the COVID-19 Era. Calvani R; Picca A; Landi F; Marzetti E J Am Med Dir Assoc; 2020 Jul; 21(7):994-995. PubMed ID: 32674834 [No Abstract] [Full Text] [Related]
16. The resurgence of convalescent plasma therapy. The Lancet Haematology Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447 [No Abstract] [Full Text] [Related]
17. Audio Interview: Capitalizing on Immune Responses to Covid-19. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859 [No Abstract] [Full Text] [Related]
18. Treatment of COVID-19: old tricks for new challenges. Cunningham AC; Goh HP; Koh D Crit Care; 2020 Mar; 24(1):91. PubMed ID: 32178711 [No Abstract] [Full Text] [Related]
19. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives. Tamburello A; Marando M Swiss Med Wkly; 2020 Apr; 150():w20264. PubMed ID: 32343358 [No Abstract] [Full Text] [Related]
20. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. Lanza F; Seghatchian J Br J Haematol; 2020 Jul; 190(1):e27-e29. PubMed ID: 32407543 [No Abstract] [Full Text] [Related] [Next] [New Search]